Comparison of Pharmaceutical markets of the EU member countries and the CIS countries
The article is aimed at analysis of pharmaceutical markets of the EU member countries and the CIS countries, their issues and development prospects. Dynamics of development of the European pharmaceutical market and its regional segmentation were studied. The main indicators of pharmaceutical markets in the key EU member countries (EU-5) were analyzed. Features of pharmaceutical markets of the Central and Eastern European EU member countries were explored. The main factors that will influence the level of state expenditures on medicines in the EU member countries were considered. The consumption of medicines per capita in different countries of the world was analyzed. Also peculiarities of State policy regulating the market of generic drugs in the EU member countries were analyzed. Features of the pharmaceutical market of the countries from the post-Soviet area, such as: structure, volume, key parameters of retail markets were studied. Features of the pharmaceutical markets of the CIS countries: Russia, Kazakhstan, and Belarus were taken into consideration. A comparison of pharmaceutical markets of the CIS countries has been formed, their key issues and the major points of growth have been identified. Also differences between pharmaceutical markets of the CIS countries and the Western markets have been identified.